Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Tacyildiz

Ibrutinib + Chemoimmunotherapy (Cit) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-Nhl) in Children (Sparkle Trial): Initial Safety, Pk, and Efficacy

Hematological Oncology

English

Related publications

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology

English

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology

Hematology

2019

English

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology

English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Tacyildiz

Ibrutinib + Chemoimmunotherapy (Cit) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-Nhl) in Children (Sparkle Trial): Initial Safety, Pk, and Efficacy

Related publications

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma